Oxcarbazepine

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Conduct Disorder

Conditions

Conduct Disorder

Trial Timeline

Apr 1, 2003 → Oct 1, 2004

NCT ID

NCT00154362

About Oxcarbazepine

Oxcarbazepine is a approved stage product being developed by Novartis for Conduct Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00154362. Target conditions include Conduct Disorder.

What happened to similar drugs?

1 of 1 similar drugs in Conduct Disorder were approved

Approved (1) Terminated (0) Active (0)

✅AripiprazoleBristol Myers SquibbApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00275912	Approved	Completed	Sep 11, 2006	Sep 28, 2007	Epilepsy, Partial Seizures
NCT00275925	Approved	Completed	Dec 1, 2005	Mar 1, 2007	Epilepsy, Partial Seizures
NCT00154362	Approved	Completed	Apr 1, 2003	Oct 1, 2004	Conduct Disorder
NCT00154323	Approved	Completed	Jan 1, 2003	Jan 1, 2006	Bipolar Disorder
NCT00050947	Phase 3	Completed	Jul 1, 2002	Feb 1, 2004	Epilepsy
NCT00050934	Phase 3	Completed	Jun 1, 2002	Jun 1, 2004	Epilepsy

Competing Products

5 competing products in Conduct Disorder

See all competitors

Product	Company	Stage	Hype Score
Symbicort pMDI with spacer device + Symbicort pMDI without spacer device	AstraZeneca	Phase 1	29
Ziprasidone Hydrochloride + Placebo	Pfizer	Phase 2	35
Aripiprazole	Bristol Myers Squibb	Approved	43
AVT03 + Denosumab	Alvotech	Phase 1	23
Custirsen + Placebo + Moxifloxacin	Achieve Life Sciences	Phase 1	19